Simplex Trading’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.08K | Sell |
607
-17,559
| -97% | -$138K | ﹤0.01% | 8290 |
|
|
2026
Q1 | $140K | Buy |
+18,166
| New | +$133K | ﹤0.01% | 4701 |
|
|
2025
Q4 | – | Sell |
-10,916
| Closed | -$118K | – | 8448 |
|
|
2025
Q3 | $201K | Buy |
10,916
+7,596
| +229% | +$122K | ﹤0.01% | 4928 |
|
|
2025
Q2 | $43K | Sell |
3,320
-429
| -11% | -$5.07K | ﹤0.01% | 6057 |
|
|
2025
Q1 | $39K | Buy |
3,749
+1,562
| +71% | +$24.8K | ﹤0.01% | 6021 |
|
|
2024
Q4 | $37K | Buy |
2,187
+806
| +58% | +$15.2K | ﹤0.01% | 6164 |
|
|
2024
Q3 | $32K | Buy |
+1,381
| New | +$29.5K | ﹤0.01% | 6288 |
|
|
2023
Q1 | – | Sell |
-3,945
| Closed | -$70.8K | – | 8946 |
|
|
2022
Q4 | $66K | Buy |
3,945
+3,074
| +353% | +$53.6K | ﹤0.01% | 5528 |
|
|
2022
Q3 | $12K | Buy |
+871
| New | +$14.6K | ﹤0.01% | 8040 |
|
|
2022
Q2 | – | Sell |
-19,710
| Closed | -$387K | – | 9882 |
|
|
2022
Q1 | $531K | Buy |
19,710
+13,339
| +209% | +$340K | ﹤0.01% | 3769 |
|
|
2021
Q4 | $235K | Buy |
6,371
+5,569
| +694% | +$227K | ﹤0.01% | 4936 |
|
|
2021
Q3 | $28K | Sell |
802
-1,273
| -61% | -$57K | ﹤0.01% | 8133 |
|
|
2021
Q2 | $70K | Sell |
2,075
-7,460
| -78% | -$253K | ﹤0.01% | 7205 |
|
|
2021
Q1 | $393K | Buy |
9,535
+8,645
| +971% | +$515K | ﹤0.01% | 3733 |
|
|
2020
Q4 | $38K | Buy |
+890
| New | +$60.3K | ﹤0.01% | 6444 |
|
|
2020
Q3 | – | Sell |
-84
| Closed | -$4.17K | – | 7738 |
|
|
2020
Q2 | $3K | Sell |
84
-3,140
| -97% | -$108K | ﹤0.01% | 7119 |
|
|
2020
Q1 | $43K | Sell |
3,224
-10,068
| -76% | -$129K | ﹤0.01% | 5279 |
|
|
2019
Q4 | $144K | Buy |
13,292
+872
| +7% | +$9.13K | ﹤0.01% | 4097 |
|
|
2019
Q3 | $127K | Buy |
12,420
+9,999
| +413% | +$108K | ﹤0.01% | 4057 |
|
|
2019
Q2 | $22K | Buy |
2,421
+2,171
| +868% | +$15.9K | ﹤0.01% | 5522 |
|
|
2019
Q1 | $1K | Buy |
250
+126
| +102% | +$645 | ﹤0.01% | 6870 |
|
|
2018
Q4 | $0 | Sell |
124
-2,671
| -96% | -$16.4K | ﹤0.01% | 6946 |
|
|
2018
Q3 | $24K | Sell |
2,795
-115
| -4% | -$958 | ﹤0.01% | 5804 |
|
|
2018
Q2 | $24K | Buy |
2,910
+1,460
| +101% | +$9.46K | ﹤0.01% | 5709 |
|
|
2018
Q1 | $7K | Sell |
1,450
-789
| -35% | -$5.44K | ﹤0.01% | 4302 |
|
|
2017
Q4 | $17K | Buy |
2,239
+2,125
| +1,864% | +$19.1K | ﹤0.01% | 3426 |
|
|
2017
Q3 | $0 | Buy |
+114
| New | +$859 | ﹤0.01% | 5843 |
|
|
2017
Q2 | – | Sell |
-448
| Closed | -$3K | – | 6039 |
|
|
2017
Q1 | $3K | Sell |
448
-449
| -50% | -$4.16K | ﹤0.01% | 4924 |
|
|
2016
Q4 | $13K | Buy |
897
+117
| +15% | +$1.75K | ﹤0.01% | 3451 |
|
|
2016
Q3 | $13K | Sell |
780
-1,098
| -58% | -$35.5K | ﹤0.01% | 3361 |
|
|
2016
Q2 | $59K | Sell |
1,878
-825
| -31% | -$26K | ﹤0.01% | 1890 |
|
|
2016
Q1 | $71K | Buy |
2,703
+1,007
| +59% | +$34.1K | 0.01% | 1640 |
|
|
2015
Q4 | $74K | Buy |
+1,696
| New | +$76.4K | 0.01% | 1593 |
|
|
2015
Q3 | – | Sell |
-818
| Closed | -$43K | – | 5460 |
|
|
2015
Q2 | $37K | Buy |
+818
| New | +$37.5K | ﹤0.01% | 1923 |
|
Other funds holding ARCT
AIM
NAMA
Simplex Trading's ARCT Position: Q2 2026 in Review
Simplex Trading reduced its Arcturus Therapeutics (ARCT) stake by 97% in Q2 2026, selling an estimated $138K and leaving 607 shares worth $4.08K. The position accounts for ﹤0.01% of the portfolio, ranked #8290.
Simplex Trading first reported a position in ARCT in Q2 2015 and has held it in 34 quarters since. The position peaked at $531K in Q1 2022. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.
- Simplex Trading held 607 shares of Arcturus Therapeutics worth $4.08K as of Q2 2026.
- Simplex Trading sold 17,559 Arcturus Therapeutics shares in Q2 2026, an estimated $138K.
- Arcturus Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #8290 holding.
- Simplex Trading first reported a position in Arcturus Therapeutics in Q2 2015 and has held it in 34 quarters since.
- Simplex Trading's Arcturus Therapeutics position peaked at $531K in Q1 2022.
- 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.
Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.